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Abstract
In this observational study we estimated the proportion of postmenopausal breast cancer patients initially
diagnosed with hormone receptor (HR)-positive locally advanced or metastatic breast cancer (LA/MBC), using
data from 6 European cancer registries (n[ 244,268 with known HR status and disease stage). Approximately
19,002 patients (7.8%) received an initial diagnosis of HR-positive LA/MBC; 74.5% (n [ 14,157) of these
received subsequent endocrine therapy as per guideline recommendations.
Background: Despite guideline recommendations, reports suggest that a proportion of patients with hormone
receptor (HR)-positive locally advanced or metastatic breast cancer (LA/MBC) might not receive endocrine therapy.
The aims of this study were to estimate the proportion of postmenopausal patients with an initial (primary) diagnosis of
HR-positive LA/MBC in Europe, and to assess the administration of endocrine treatment in these patients.
Materials and Methods: Fourteen national and regional cancer registries across Europe were invited to participate in
this observational study. Six registries each provided anonymized clinical information on > 5000 postmenopausal
women with breast cancer diagnosed between January 2000 and December 2014, including age at diagnosis,
estrogen and/or progesterone receptor status, disease stage, and receipt of endocrine therapy. The proportion of
patients with an initial diagnosis of HR-positive LA/MBC and, of these, the proportion who received endocrine therapy,
was calculated. Results: Registries from Belgium, England, Ireland, Norway, The Netherlands, and Munich,
Germany provided data. In total, 316,680 postmenopausal women were diagnosed with breast cancer, including
244,268 with known HR status and disease stage. Of these patients, 19,002 (7.8%) had a primary diagnosis of
HR-positive LA/MBC. This proportion ranged from 5.4% (N ¼ 4484) in England to 12.7% (N ¼ 4085) in Germany.
Most of these patients (n ¼ 14,157; 74.5%) received endocrine treatment, ranging from 55.5% (n ¼ 445) in1Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
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Endocrine Therapy in Patients With HR-Positive LA/MBCNorway to 88.1% (n ¼ 443) in Belgium. Conclusion: These results indicate that a sizeable proportion of post-
menopausal patients in Europe received a primary diagnosis of HR-positive LA/MBC, and that almost three-
quarters received subsequent endocrine therapy as per guideline recommendations.
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registriesIntroduction
Breast cancer is one of the most prevalent cancers among women,1
and most breast cancers are classiﬁed as hormone receptor (HR)-
positive at diagnosis.2 Endocrine therapy is the current standard
treatment for patients withHR-positive breast cancer, in the adjuvant
setting as well as for advanced disease, in the absence of rapidly pro-
gressive disease or proven endocrine resistance.3-5 Therefore, only a
small proportion of patients with locally advanced (LA) or metastatic
breast cancer (MBC) might be expected to be endocrine therapy-
naive. This patient subgroup might comprise patients who received
an initial (primary) diagnosis of HR-positive LA/MBC, and patients
with recurrence ormetastasis from an early stage breast cancer who did
not receive endocrine therapy for their previous disease. There are
limited data reporting the prevalence of these patient subgroups.
Studies of small retrospective databases have reported that of all
patients with known HR status, approximately 13% to 17% had a
primary diagnosis of HR-positive advanced disease (LA/MBC).6-8
However, these studies did not assess subsequent therapy in this
patient group, and, to our knowledge, a comprehensive evaluation
of the size of this patient population has not been performed.
The aims of this study were to ascertain the proportion of
postmenopausal women with HR-positive LA/MBC at primary
diagnosis, and to calculate the proportion of these patients who
received endocrine therapy.
Materials and Methods
Study Population
This was an observational, retrospective study conducted by the
European Registration of Cancer Care collaboration, which recruited
patients from national and regional cancer registries across Europe.
Participating registries provided anonymized data on postmenopausal
women diagnosed with breast cancer, and only registries that provided
data on > 5000 patients were included in the analysis.
Patients who met the following inclusion criteria were eligible for
inclusion in the study: female sex, postmenopausal (55 years of age
or older), and diagnosed with invasive breast cancer according to the
International Classiﬁcation of Diseases for Oncology (third edition)9
breast cancer criteria between January 2000 and December 2014.
The population-based cohort included all patients fulﬁlling the
inclusion criteria. For this type of study, ethical approval and
informed consent were not required.
Data Collection
Anonymized data were collated from the cancer registries, which
employ trained registrars to collect data from patient hospital ﬁles- Clinical Breast Cancer August 2018after notiﬁcation by pathology laboratories, or from other sources
such as radiation facilities and hospital inpatient databases. Most
registries recorded the ﬁrst line of treatment prescribed within a year
of diagnosis.
Patient clinical information requested included: date of diagnosis,
age of patient, and tumor, node, metastasis [TNM] stage of tumor at
diagnosis (clinical stage) and pathological stage. LA breast cancer was
deﬁned as TNM stage IIIb or IIIc (according to the TNM Classiﬁ-
cation of Malignant Tumours, sixth and seventh editions10,11); MBC
was deﬁned as TNM stage IV. Estrogen receptor (ER) and proges-
terone receptor (PR) status (positive, negative, or unknown) was
obtained, along with information on subsequent endocrine therapy
(yes or no). HR-positive status was deﬁned as having pathologically
conﬁrmed ER-positive and/or PR-positive breast cancer. Patients
with known HR status were selected for inclusion in further analyses.
Missing data (stage and HR status) for patients were classiﬁed as
unknown; these patients were initially included in the cohort.
Data Analysis
Using the pooled as well as country-speciﬁc data, the proportion
of patients with HR-positive LA/MBC at primary diagnosis was
calculated, as well as the proportion of patients who received
subsequent endocrine treatment. Descriptive results are presented;
no formal statistical analyses were performed, because raw data were
not provided by all registries.
Results
Patient Population
Fourteen cancer registries in Europe were invited to participate in
the study. Five national registries (Belgium, England, Ireland,
Norway, and The Netherlands) and 1 regional registry (Munich,
Germany), who each contributed data from > 5000 patients,
participated in this study. Registries that did not participate either
did not respond to the invitation, or did not record the relevant data
in the format required.
Data received (January 2000 to December 2014) were analyzed
in November 2016. Data from Belgium were included for 2008
only, because this was the only year for which HR status was
available. At the time of this analysis, not all diagnosed patients in
England for 2014—or in Ireland for 2013 and 2014—were
registered in the cohort.
In total, data for 316,680 postmenopausal women with breast
cancer were collected (Table 1). Median patient age at diagnosis
ranged across countries from 67.0 years in Ireland to 69.0 years in
England and Belgium.
Table 1 Identiﬁcation of HR-Positive Patients With Known Disease Stage, Overall and According to Country
Englanda Norway Irelandb Germanyc Belgiumd The Netherlands Total
All Postmenopausal Breast Cancer Cases 2000-2014, n 125,408 27,159 19,179 40,181 6658 98,095 316,680
Median Age of Included Patients, Years (Range) 69.0 (55.0-112.0) 67.6 (55.0-105.6) 67.0 (55.0-101.0) 68.1 (55.0-107.5) 69.0 (55.0-99.0) 68.7 (55.0-103.0)e
Assessed for HR (ER and/or PR) Status and Known Disease
Stage, n (% All Breast Cancer Cases)
83,370 (66.5) 12,962 (47.7) 15,393 (80.3) 32,218 (80.2) 4848 (72.8) 95,477 (97.3) 244,268 (77.1)
Assessed for ER status, n (% of All Breast Cancer Cases) 81,646 (65.1) 14,414 (53.1) 16,059 (83.7) 37,378 (93.0) 5706 (85.7) 95,782 (97.6) 250,985 (79.3)
ER-Positive, n (% Assessed for Known ER Status) 70,690 (86.6) 12,267 (85.1) 13,254 (82.5) 32,385 (86.6) 4863 (85.2) 81,591 (85.2) 215,050 (85.7)
ER-Negative, n (% Assessed for Known ER Status) 10,956 (13.4) 2147 (14.9) 2805 (17.5) 4993 (13.4) 843 (14.8) 14,191 (14.8) 35,935 (14.3)
Assessed for PR Status, n (% of All Breast Cancer Cases) 37,188 (29.7) 14,305 (52.7) 13,137 (68.5) 37,301 (92.8) 5685 (85.4) 93,529 (95.3) 201,145 (63.5)
PR-Positive, n (% Assessed for Known PR Status) 25,047 (67.4) 9356 (65.4) 8292 (63.1) 29,134 (78.1) 4287 (75.4) 61,714 (66.0) 137,830 (68.5)
PR-Negative, n (% Assessed for Known PR Status) 12,141 (32.6) 4949 (34.6) 4845 (36.9) 8167 (21.9) 1398 (24.6) 31,815 (34.0) 63,315 (31.5)
HR-Positive With Known Disease Stage, n (% All Breast
Cancer Cases)
53,197 (42.4) 11,012 (40.5) 12,693 (66.2) 28,264 (70.3) 4197 (63.0) 81,837 (83.4) 191,200 (60.4)
Abbreviations: ER ¼ estrogen receptor; HR ¼ hormone receptor; PR ¼ progesterone receptor.
aData from 2014 were not included (data not complete at the time of this analysis).
bData from 2013 and 2014 were not included (data not complete at the time of this analysis).
cRegional data set.
dData for 2008 only.
eAge reported by The Netherlands registry as mean values, rather than median.
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Of the female postmenopausal breast cancer patients included in
the analysis, 77.1% had known disease stage and were assessed for
HR status (n ¼ 244,268 of 316,680). There was variation in the
availability of HR status across the different countries, ranging from
47.7% (n ¼ 12,962) in Norway to 97.3% (n ¼ 95,477) in The
Netherlands. ER status was available for 250,985 patients, 85.7%
(n ¼ 215,050) of whom were ER-positive. PR status was available
for 201,145 patients, of whom 68.5% (n ¼ 137,830) were PR-
positive. The proportion of patients who had ER-positive breast
cancer ranged from 82.5% (n ¼ 13,254) in Ireland to 86.6% in
England (n ¼ 70,690) as well as Germany (n ¼ 32,385), and those
with PR-positive breast cancer ranged from 63.1% (n ¼ 8292) in
Ireland to 78.1% (n ¼ 29,134) in Germany.
Hormone Receptor-Positive LA/MBC at Primary
Diagnosis
Disease stage and HR status was known for 244,268 patients. Of
these, 7.8% (n ¼ 19,002 of 244,268) had a primary diagnosis of
HR-positive LA/MBC, of which 3.5% (n ¼ 8540 of 244,268) were
LA and 4.3% (n ¼ 10,462 of 244,268) were MBC (Figure 1;
Table 2).
The proportion of patients with a primary diagnosis ofHR-positive
LA/MBC ranged across countries from 5.4% (n¼ 4484) in England
to 12.7% (n ¼ 4085) in Germany. Of patients with a primary diag-
nosis of HR-positive LA/MBC, 44.9% (n ¼ 8540 of 19,002) were
diagnosed with LA breast cancer, and 55.1% (n¼ 10,462 of 19,002)
were diagnosed withMBC (Figure 2; Table 2). The percentage varied
between countries (LA: 29.8% (n ¼ 374) in Ireland to 52.4%
(n ¼ 4126) in The Netherlands; MBC: 47.6% (n ¼ 3745) in The
Netherlands to 70.2% (n ¼ 883) in Ireland).
Most patients with a primary diagnosis of LA/MBC went on to
receive subsequent endocrine therapy (74.5%; n ¼ 14,157 of
19,002; Figure 3; Table 2). This proportion ranged across countries
from 55.5% (n ¼ 445) in Norway to 88.1% (n ¼ 443) in Belgium.
In total, 25.5% (n ¼ 4845 of 19,002) of patients with a primary
diagnosis of HR-positive LA/MBC did not receive endocrine
therapy.Figure 1 Proportion of Patients With Known HR Status and Disease
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This large retrospective review of data from > 300,000 patient
cases from 1 regional registry and 5 national European registries
provides an estimate of the prevalence of postmenopausal women
with a primary diagnosis of HR-positive advanced disease. In
summary, approximately 8% of women (> 19,000 patients) with
known HR status and disease stage were diagnosed with LA/MBC
at primary diagnosis. These results indicate that there might be a
substantial population of women with a primary diagnosis of
HR-positive LA/MBC, and that the size of this population could
vary between European countries. Furthermore, this study shows
that almost three-quarters (74.5%) of these patients received
subsequent endocrine treatment. However, it should be noted that
treatment compliance was not recorded for this study.
Although most patients were prescribed endocrine therapy,
approximately one-quarter of patients (25.5%) did not receive
endocrine therapy after a primary diagnosis of HR-positive LA/
MBC. Some patients might not have received endocrine therapy
because of chemotherapy being the preferred treatment option
(ie, in patients with rapidly progressing disease, or visceral
spread3,4). In addition, we investigated patients with stage IIIB,
stage IIIC, and stage IV breast cancer, and did not ascertain whether
any of these patients underwent surgery with curative intent.
Guidelines recommend surgery for LA breast cancer only after
initial systemic therapy,3,4 whereas policies on surgery for metastatic
disease differ according to country, and can depend on the disease
localization and number of metastases. The results of larger
prospective studies on the role of surgery for patients who present
with MBC at primary diagnosis are eagerly awaited.3,4
Despite similar proportions of patients with a primary diagnosis
of HR-positive LA/MBC (5%-13%), the percentage of these who
received subsequent endocrine therapy differed between countries,
ranging from 55.5% in Norway to 88.1% in Belgium. This could
reﬂect potential differences in practice between cancer registries in
the different countries, which might have led to variances in the
degree of underdocumentation of endocrine therapy, or could
represent actual differences in the administration of endocrine
therapy in these countries. For example, a recent physician case-Stage Who Had LA/MBC at Primary Diagnosis
ermany
 32,218)
Belgium
(n = 4848)
The
Netherlands
(n = 95,477)
Total
(N = 244,268)
 LA/MBC at primary diagnosis 
reast cancer cases
87.3 89.6 91.8 92.2
12.7 10.4 8.2 7.8
cally advanced cases might be under-represented in the Irish data set (see Discussion).
Table 2 Patients With a Primary Diagnosis of HR-Positive LA/MBC and Endocrine Therapy Use, Overall and According to Country
Englanda Norway Irelandb Germanyc Belgiumd
The
Netherlands Total
Patients Assessed for HR Status and
Disease Stage, n
83,370 12,962 15,393 32,218 4848 95,477 244,268
HR-Positive LA/MBC at Primary Diagnosis,
n (% of Patients Assessed for HR Status and
Disease Stage)
4484 (5.4) 802 (6.2) 1257 (8.2) 4085 (12.7) 503 (10.4) 7871 (8.2) 19,002 (7.8)
LA, n (% HR-Positive LA/MBC at Primary
Diagnosis)
1772 (39.5) 384 (47.9) 374 (29.8) 1648 (40.3) 236 (46.9) 4126 (52.4) 8540 (44.9)
MBC, n (% HR-Positive LA/MBC at
Primary Diagnosis)
2712 (60.5) 418 (52.1) 883 (70.2) 2437 (59.7) 267 (53.1) 3745 (47.6) 10,462 (55.1)
With Subsequent Endocrine Therapy, n (%
HR-Positive LA/MBC at Primary Diagnosis)
2796 (62.4) 445 (55.5)e 1019 (81.1) 2526 (61.8) 443 (88.1) 6928 (88.0) 14,157 (74.5)
Abbreviations: HR ¼ hormone receptor; LA ¼ locally advanced; MBC ¼ metastatic breast cancer.
aData from 2014 not included (data not complete at the time of this analysis).
bData from 2013 and 2014 not included (data not complete at the time of this analysis).
cRegional data set.
dData for 2008 only.
eEndocrine therapy unknown in some patients.
Esther Bastiaannet et alreporting database study of > 27,000 postmenopausal women with
HR-positive MBC showed that, in routine clinical practice,
chemotherapy-based regimens were used more commonly than
endocrine therapy as ﬁrst-line treatment (in the range of
51.3%-69.1% vs. 30.1%-47.2%, respectively) in France, Germany,
Italy, and Spain, between 2004 and 2013.12
Several recent phase III clinical trials have evaluated different treat-
ment options for patients with HR-positive LA/MBC who have not
received previous endocrine therapy. The recently completed Fulves-
trant and AnastrozoLE COmpared in hormonal therapy-Naïve
advanced breast cancer (FALCON) trial (NCT01602380) assessed the
efﬁcacy of fulvestrant 500 mg versus anastrozole as ﬁrst-line endocrine
therapy in postmenopausal women with HR-positive advanced breast
cancer who had not received previous endocrine therapy (n ¼ 462).Figure 2 Proportion of Patients With Either LA or Metastatic Breast
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vival was signiﬁcantly improved with fulvestrant compared with anas-
trozole.13 In addition, the PALbociclib: Ongoing trials in the
Management of breast cAncer-2 (PALOMA-2) (NCT01740427)14
and Mammary ONcology Assessment of LEE011’s Efﬁcacy and
SAfety (MONALEESA-2) (NCT01958021)15 studies compared
letrozole in combination with palbociclib and ribociclib, respectively,
with letrozole alone, and included a considerable proportion of patients
(43.7% and 48.2%, respectively) who had not received previous
endocrine therapy. In both studies, the combination of letrozole with a
cyclin-dependent kinase 4/6 inhibitor was reported to be signiﬁcantly
more effective than letrozole alone.
In addition to the registries included in the main analysis, a data
set was also obtained from Barcelona, Spain, comprising 338Cancer at Primary Diagnosis
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Figure 3 Proportion of Patients With HR-Positive LA/MBC at Primary Diagnosis Who Went On to Receive Subsequent Endocrine
Therapy
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e618patients with postmenopausal breast cancer. This was not included
in the main analysis, because the sample size was too small for
meaningful assessment. In this data set, ER status was available for
337 patients (99.7%), of whom 267 (79.2%) were ER-positive. PR
status was available for 334 patients (98.8%), and 194 (58.1%)
were PR-positive. Of the 334 patients with known disease stage and
HR status, 83 (24.9%) had a primary diagnosis of LA/MBC (67
patients with LA, and 16 patients with MBC). The proportion of
patients in Barcelona with a primary diagnosis of HR-positive LA/
MBC was larger than that observed in the main data set in this
study (24.9% vs. 7.8%), possibly because of the small sample size of
the Barcelona data set. Of the 83 patients with a primary diagnosis
of HR-positive LA/MBC in Barcelona, 61 (73.5%) received
subsequent endocrine therapy, a proportion similar to the main data
set (74.5%).
The proportion of patients in Norway assessed for HR status and
with known disease stage was low (47.7%), likely because of issues
in reporting HR status and disease stage to the registry. In com-
parison, The Netherlands had a high proportion of patients who
were assessed for HR status (97.3%). Compared with the other
countries, Ireland had a markedly lower proportion of HR-positive
advanced breast cancer cases that were LA (29.8% vs.
39.5%-52.4%). A possible explanation for this is a potential un-
derestimation of cases of LA breast cancer in Ireland, compared with
other participating countries. Until recently, the Irish National
Cancer Registry coded breast cancer stage using the ﬁfth edition16 of
the TNM Classiﬁcation of Malignant Tumours. However, most
countries adopted the sixth edition10—which markedly revised the
classiﬁcation of lymph node metastases—soon after it was published
in 2002, and, from 2010, the seventh edition.11 As a result, some
cases that might have been assigned as stage IIIc in countries that
adhered to criteria in the sixth10 and seventh11 editions of the TNM- Clinical Breast Cancer August 2018Classiﬁcation of Malignant Tumours were not included or, in the case
of ipsilateral supraclavicular node involvement, were categorized as
stage IV in the Irish data set. This might have applied to a lesser
extent (for cases in 2000 and 2001) in other countries’ data sets.
Overall, the proportion of patients in this study with known
HR status who had a primary diagnosis of HR-positive LA/MBC
was lower (7.8%) than in previously published estimates
(approximately 13%-17%).6-8 However, the generalizability of
the previous ﬁndings is limited, because they were derived from a
small number of patient records. In addition, the range of years
and geographic regions included in these studies differed from the
present study, and comparisons should therefore be interpreted
with caution.
Limitations of this study include those inherent to any database
study, such as potential misclassiﬁcation and missing data. Not all
registries were able to contribute data for all of the speciﬁed
diagnostic parameters (eg, HR status was not available for all pa-
tients). In addition, by restricting this analysis to postmenopausal
patients older than 55 years of age, this study excluded younger
postmenopausal patients. Therefore, these results might not fully
represent the population of patients with HR-positive breast
cancer.
The subpopulation of patients with HR-positive LA/MBC
without previous endocrine therapy might also include patients with
a recurrence of early breast cancer who did not receive endocrine
therapy for their early disease. These patients were not considered in
this study, because of limitations in the way recurrences were
recorded by most participating registries. Therefore, the proportion
of postmenopausal patients reported in this study as having a pri-
mary diagnosis of HR-positive LA/MBC could be an underestimate
of the total population of patients with HR-positive LA/MBC who
have not received previous endocrine therapy. In this study, data on
Esther Bastiaannet et alrecurrence was obtained from German and Norwegian registries
(data not shown). On the basis of this small data set (n ¼ 3260),
patients with HR-positive LA/MBC who did not receive endocrine
therapy after a previous diagnosis of early breast cancer could
account for approximately 4% of all postmenopausal breast cancer
patients with known HR status and disease stage.
It should be noted that these results might only be applicable to
Europe. However, the prevalence of patients with a primary diagnosis
of HR-positive LA/MBC might be higher in developing countries,
where patients are more likely to present with advanced disease.17
Elderly patients with breast cancer, who might not be included in
routine breast cancer screening programs,18 are also more likely to
present with advanced disease.19 Therefore, it would also be inter-
esting to investigate endocrine therapy in this speciﬁc patient popu-
lation, which might have fewer perceived treatment options.20
Conclusion
Overall, the results of the present study indicate that a sizeable
population of patients presented with a primary diagnosis of HR-
positive LA/MBC, nearly three-quarters of whom went on to
receive endocrine therapy.
Clinical Practice Points
 Endocrine therapy is recommended for patients with HR-
positive breast cancer in the absence of rapidly progressing dis-
ease or visceral crisis.
 Several recent studies have assessed different treatment options in
patients with HR-positive LA or MBC who have not previously
received endocrine therapy (ie, are endocrine therapy-naive).
This patient population might comprise those who received an
initial diagnosis of HR-positive LA/MBC, or who did not receive
endocrine therapy for their early disease. Previous estimates as to
the size of this population are on the basis of small retrospective
studies. However, to our knowledge, a comprehensive estimate
has not yet been performed.
 This retrospective, observational study used data from 6 Euro-
pean cancer registries (Belgium, England, Ireland, Norway, the
Netherlands, and Munich, Germany) to estimate the proportion
of postmenopausal patients with breast cancer who received an
initial diagnosis of HR-positive LA/MBC between January 2000
and December 2014.
 Of 244,268 patients with breast cancer and known HR status and
disease stage, 19,002 (7.8%) received an initial diagnosis of HR-
positive LA/MBC. Almost three-quarters of these patients (n ¼
14,157; 74.5%) went on to receive endocrine therapy in line with
guideline recommendations. This proportion differed between
countries, from 55.5% in Norway to 88.1% in Belgium, and
could reﬂect potential differences in recording practices between
cancer registries in Europe, or actual differences in the adminis-
tration of endocrine therapy in these countries.Acknowledgments
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